The Food and Drug Administration (FDA) in the USA has granted Orphan Drug Designation to ISA Pharmaceuticals BV, an immunotherapy company, for its lead product ISA101b, intended for the treatment of Human Papilloma Virus type 16 (HPV16)-positive cervical cancer, it was reported on Wednesday.
The therapeutic is a clinical-stage immunotherapy targeting HPV16-induced diseases and induces specific immune responses to the oncogenic E6 and E7 proteins of HPV16 and is based on ISA Pharmaceuticals BV's proprietary Synthetic Long Peptide technology. It is designed to mount a highly specific, broad and durable, T-cell mediated attack by the immune system on tumours that are positive for human papilloma virus type 16
ISA101 has indicated that it is an effective monotherapy in patients with early stage, HPV16 positive, premalignant neoplasias.
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Illumina's GRAIL divestment plan receives EC approval
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Ondine Biomedical's Steriwave approved for use by HCA UK
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial
Syros receives Fast Track Designation from FDA for tamibarotene in AML